• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.

作者信息

Mauguen Audrey, Michiels Stefan, Rondeau Virginie

机构信息

a Univ. Bordeaux ISPED , Centre INSERM U1219-Epidémiologie-Biostatistique , Bordeaux , France.

b INSERM, ISPED , Centre INSERM U1219-Epidémiologie-Biostatistique , Bordeaux , France.

出版信息

J Biopharm Stat. 2017;27(6):1043-1053. doi: 10.1080/10543406.2017.1295249. Epub 2017 Mar 20.

DOI:10.1080/10543406.2017.1295249
PMID:28319455
Abstract

Clinical trial duration may be a concern in clinical research, especially in cancer trials where the endpoint is overall survival. A surrogate endpoint can be used as an auxiliary variable to analyze the treatment effect earlier. At an early time point, the high number of censored observations can be compensated by the imputation of the unobserved deaths times. We propose to use predictions of the risk of death from a joint model for a recurrent event and a terminal event, which account for disease relapse information. Two imputation methods were compared: sampling from the estimated parametric distribution of the survival time and sampling using its nonparametric estimation. The treatment effect and its standard error were estimated via multiple imputations. The performances of the two methods were compared in terms of bias in the estimates, standard errors, and coverage probability. Both methods were then retrospectively applied to two randomized clinical trials studying the effect of adjuvant chemotherapy in breast cancer patients.

摘要

相似文献

1
Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.
J Biopharm Stat. 2017;27(6):1043-1053. doi: 10.1080/10543406.2017.1295249. Epub 2017 Mar 20.
2
Survival analysis using auxiliary variables via non-parametric multiple imputation.通过非参数多重填补法使用辅助变量进行生存分析。
Stat Med. 2006 Oct 30;25(20):3503-17. doi: 10.1002/sim.2452.
3
Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.利用辅助信息提高临床试验效率:多状态治愈模型的应用
Biometrics. 2015 Jun;71(2):460-8. doi: 10.1111/biom.12281. Epub 2015 Jan 13.
4
Survival analysis using auxiliary variables via multiple imputation, with application to AIDS clinical trial data.通过多重填补使用辅助变量的生存分析及其在艾滋病临床试验数据中的应用。
Biometrics. 2002 Mar;58(1):37-47. doi: 10.1111/j.0006-341x.2002.00037.x.
5
Multiple imputation for interval censored data with auxiliary variables.带有辅助变量的区间删失数据的多重填补
Stat Med. 2007 Feb 20;26(4):769-81. doi: 10.1002/sim.2581.
6
Risk-stratified imputation in survival analysis.生存分析中的风险分层插补。
Clin Trials. 2013 Aug;10(4):530-9. doi: 10.1177/1740774513493150. Epub 2013 Jul 1.
7
Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.利用治愈模型和多重插补,将复发作为总生存的辅助变量。
Clin Trials. 2011 Oct;8(5):581-90. doi: 10.1177/1740774511414741. Epub 2011 Sep 15.
8
A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.以无进展生存期作为区间删失的事件发生时间终点的统计问题综述。
J Biopharm Stat. 2013;23(5):986-1003. doi: 10.1080/10543406.2013.813524.
9
Bias and Precision of the "Multiple Imputation, Then Deletion" Method for Dealing With Missing Outcome Data.处理缺失结局数据的“多次插补,然后删除”方法的偏倚和精密度
Am J Epidemiol. 2015 Sep 15;182(6):528-34. doi: 10.1093/aje/kwv100. Epub 2015 Sep 2.
10
Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint.从替代指标推断真实终点:在一项关于真实终点只有部分信息的整群随机对照试验中的应用。
BMC Med Res Methodol. 2003 Sep 24;3:17. doi: 10.1186/1471-2288-3-17.

引用本文的文献

1
Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors".
Drugs. 2017 Jul;77(10):1139-1140. doi: 10.1007/s40265-017-0761-x.